ALS drug safety check: new study tests Long-Term effects

NCT ID NCT07571200

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study looks at the long-term safety of an experimental drug called LY4256984 for people with ALS. It enrolls up to 32 participants who have completed a prior ALS trial. The study will follow them for at least 96 weeks to see how well the drug is tolerated over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4256984
What this could lead to: If successful, this could help confirm that these experimental drugs are safe enough to use in larger trials for ALS.
What could go wrong: This is a very early (Phase 1) study with only 32 people. It focuses on safety, not effectiveness, so it may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Hospital Universitari de Bellvitge
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, 08907, Spain
Hospital Universitari i Politecnic La Fe
NOT_YET_RECRUITING

Valencia, 46026, Spain
McGill University Health Centre
RECRUITING

Montreal, H4A 3J1, Canada
Sunnybrook Research Institute
NOT_YET_RECRUITING

Toronto, M4N 3M5, Canada
UZ Leuven
NOT_YET_RECRUITING

Leuven, 3000, Belgium
Universitaetsklinikum Ulm
NOT_YET_RECRUITING

Ulm, 89081, Germany
Universitair Medisch Centrum Utrecht
NOT_YET_RECRUITING

Utrecht, 3584 CX, Netherlands
University Hospital - London Health Sciences Centre
NOT_YET_RECRUITING

London, N6A 5A5, Canada
Universitätsklinikum Schleswig-Holstein
NOT_YET_RECRUITING

Lübeck, 23538, Germany
Universitätsmedizin Rostock
NOT_YET_RECRUITING

Rostock, 18147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.